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Abstract
Background Ethnic differences in drug susceptibility and
toxicity are a major concern, not only in drug development
but also in the clinical setting. We review the toxicity
profiles of docetaxel according to dose and ethnicity.
Methods We analyzed phase II and III clinical trials that
included a once-every-3-weeks single-agent docetaxel arm.
Logistic regression analysis was applied to identify the
significant variables affecting the reported incidence of
docetaxel-induced severe neutropenia.
Results Multivariate logistic regression analysis identi-
fied studies conducted in Asia [odds ratio (OR) 19.0; 95%
confidence interval (95% CI) 3.64–99.0] and docetaxel
dose (OR 1.08; 95% CI 1.03–1.13) as independent vari-
ables for the incidence of grade 3/4 neutropenia.
Conclusions There is a significant difference in the inci-
dence of docetaxel-induced severe neutropenia between
Asian and non-Asian clinical studies. Physicians and
pharmacists should consider ethnic diversity in docetaxel
toxicity when interpreting the results of clinical trials.
Keywords Ethnic differences  Docetaxel  Logistic
regression  Neutropenia
Introduction
One of the major concerns in the international harmoni-
zation of drug development is the issue of pharmacoeth-
nicity. Pharmacoethnicity can be described as ethnic
diversity in drug response or toxicity, which includes a
large number of factors including genetic and environ-
mental components and social divergence [1, 2].
In the area of oncology, some reports have discussed
ethnic differences in treatment effects and toxicity. For
example, gefitinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor that has been used for the
treatment of EGFR-positive non-small-cell lung cancer,
was reported to have a minimal effect on survival in a large
multi-regional placebo-controlled phase III trial, despite a
significant increase in survival in patients of Asian origin
[3]. This diversity might be explained, in part, by differ-
ences in the frequency of EGFR mutations, a major pre-
dictive factor of gefitinib efficacy [4]. Other studies
examined the combination of irinotecan and cisplatin for
the treatment of advanced small cell lung cancer. The use
of irinotecan plus cisplatin for the treatment of extensive-
stage small cell lung cancer was first reported by Japanese
researchers (JCOG 9511), and it was shown to have a
superior survival effect over the conventional standard
regimen of etoposide plus cisplatin [5]. However, trials in
North America failed to confirm the survival benefit of
irinotecan-containing regimens [6, 7]. One of these studies,
the SWOG S0124 trial, included pharmacogenomic
investigations. The authors stated the potential importance
of pharmacogenomics in interpreting the results of clinical
trials in cancer therapy [6].
In 2008, the combination of 75 mg/m2 docetaxel with
prednisolone was approved in Japan for the treatment of
hormone-refractory prostate cancer on the basis of results
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from a Japanese phase II trial [8] and a Western phase III
trial (TAX327) [9]. In these two clinical studies, several
differences were found, including the doses of docetaxel
and their outcomes and safety profiles. In the Japanese
phase II trial, 70 mg/m2 docetaxel was used, whereas the
TAX327 trial used 75 mg/m2 docetaxel. Grade 3/4 neu-
tropenia and febrile neutropenia occurred in 93.0 and
16.3% of patients in the Japanese study compared to 32 and
3% of patients in the TAX327 trial, respectively. These
results suggested that docetaxel was more toxic to Japanese
patients, despite the use of a lower dose. In Japan, doce-
taxel has been approved at doses of 60–70 mg/m2 for the
treatment of gastric cancer, non-small-cell lung cancer,
esophageal cancer, ovarian cancer, and uterine corpus
cancer. These approved doses of docetaxel in Japan are
much lower than those in Western countries.
According to these observations, we analyzed the dif-
ferences in the incidence of docetaxel-induced severe
neutropenia between clinical trials conducted in Asian and
non-Asian countries using published data as a model to
study ethnic diversity in drug susceptibility.
Materials and methods
Search strategy
Phase II and III clinical trials that included a treatment arm
of docetaxel monotherapy administered at 3-week intervals
were considered in this review. Meeting abstracts were
excluded. Studies that used glucocorticoids with docetaxel
were also included. Only reports written in English or
Japanese were included in the analysis.
An electronic database search was performed using
PubMed, the Cochrane Controlled Trials Register by Ovid
(EBM reviews, 4th quarter, 2009), and Ichushi-Web (a
domestic medical literature database service provided by
the NPO Japan Medical Abstracts Society) on November
30, 2009. The keyword used for the electronic database
search of PubMed was ‘‘docetaxel’’ with limitations by the
type of articles of ‘‘clinical trials, phase II’’, or ‘‘clinical
trials, phase III’’. For the other databases, we used
‘‘docetaxel’’ as a keyword.
Selection criteria
Surveys and retrospective studies were not included in the
analysis. Reports of interim analysis were also excluded. In
addition, reports that contained the incidence of grade 3/4
neutropenia only as a percentage of treatment courses were
excluded. Finally, studies adopting primary prevention with
granulocyte-colony stimulating factor were also excluded.
Study selection
Two authors independently assessed the titles and abstracts
of all identified articles. Disagreements between the
reviewers were resolved by consensus. Two authors eval-
uated the full text of the selected papers and determined
their inclusion or exclusion in the analysis according to the
eligibility criteria.
Data extraction
Two authors extracted data for trial phase, treatment line,
types of malignancy, number of patients treated with
docetaxel, dose of docetaxel, median age, percentage of
females, percentage of patients whose performance status
(defined by the World Health Organization/Eastern Coop-
erative Oncology Group) was [1, the region where the
study was conducted, and the incidence of grade 3/4 neu-
tropenia as a percentage of patients.
Statistical analysis
Univariate and multivariate analyses were conducted to
identify the factors influencing the higher incidence of
grade 3/4 neutropenia in the docetaxel monotherapy arm
in each report. A [70% incidence of grade 3/4 neutro-
penia was defined as a higher incidence. The dose of
docetaxel, percentage of females, median age of partici-
pants, percentage of patients whose performance status
was [1, treatment line, trial phase, and the region where
the study was mainly conducted were considered as
candidate variants. The treatment line was classified into
2 groups: the adjuvant, neoadjuvant, and first line were
encoded as 0, while the second line or subsequent lines
were encoded as 1. The region where the study was
mainly conducted was grouped as Asia or non-Asia. The
dose of docetaxel, median age of participants, and per-
centage of patients whose performance status was [1
were forcibly included into the multivariate analysis
because they are known risk factors for the incidence of
neutropenia with docetaxel. The variables that showed a
moderate relationship (p \ 0.2) with a higher incidence of
grade 3/4 neutropenia in the univariate analysis were
included in the multivariate analysis. The final model was
built by stepwise logistic regression. The variables were
selected using Wald’s likelihood ratio, with p values of
\0.1 for exclusion and \0.05 for inclusion. A Hosmer–
Lemeshow goodness-of-fit test was performed to examine
the calibration of the model. All statistical analyses were
performed using SPSS statistics version 17.0 (SPSS Japan
Inc., Tokyo, Japan).
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Results
Literature search
We identified 1010 citations by database search, of which
153 articles were retrieved and reviewed. We excluded
papers that did not contain adequate patient demographics
or outcomes (n = 21), studies with a dosage regimen that
did not meet our criteria (n = 8), and review papers or
papers containing combined analyses (n = 4; Fig. 1).
Ultimately, 128 arms from 120 studies were used for fur-
ther analysis [8–127].
Characteristics of the reports
The characteristics of the reports reviewed are presented in
Table 1. The size and number of the study arms classified
by docetaxel dose were 1535 patients in 24 arms, 25
patients in 1 arm, 274 patients in 6 arms, 4034 patients in
30 arms, and 3880 patients in 67 arms for 60, 66, 70, 75,
and 100 mg/m2 docetaxel, respectively. Of these arms, the
numbers of studies conducted in Asia and their participants
were 1384 patients in 23 arms, 25 patients in 1 arm, 225
patients in 5 arms, 141 patients in 3 arms, and 35 patients
in 1 arm for 60, 66, 70, 75, and 100 mg/m2 docetaxel,
respectively. The minimum number of participants in an
arm was 12. The majority of the participants were non-
small-cell lung cancer and breast cancer patients. The
majority of studies conducted in Asia were Japanese
studies (1609 Japanese participants in 28 arms out of 1810
Asian participants in 33 arms). The others Asian studies
were conducted in South Korea, Taiwan, and Singapore.
All of the studies conducted in Japan used docetaxel at
doses of 70 mg/m2 or lower. In particular, phase III trials
conducted in Asia were performed using 60 mg/m2 doce-
taxel. There were 10 reports written in Japanese that con-
tained 745 Japanese participants.
Distribution of the reported incidence of grade 3/4
neutropenia
The relationship between the dose of docetaxel and the
incidence of grade 3/4 neutropenia is presented in Fig. 2.
The weighted means of the reported incidence of grade 3/4
neutropenia, which were calculated by dividing the total
number of participants who experienced grade 3/4Fig. 1 Study selection
Table 1 Characteristics of the study arms
Docetaxel dose (mg/m2) 60 66 70 75 100
Trial phase II III II III II III II III II III
Number of study arms (Asia) 19 (19) 5 (4) 1 (1) 0 (0) 6 (5) 0 (0) 18 (3) 12 (0) 53 (1) 12 (0)
Sample size (by arm)
12–50 10 0 1 0 5 0 12 0 46 2
51–100 9 2 0 0 1 0 6 2 8 2
101–200 0 2 0 0 0 0 0 4 1 6
C201 0 1 0 0 0 0 0 6 0 2
Total number of participants
(in Asian studies)
839 (839) 696 (545) 25 (25) 0 (0) 274 (225) 0 (0) 824 (141) 3210 (0) 2290 (35) 1590 (0)
Types of tumor
Non-small-cell lung 5 3 1 0 1 0 11 8 8 5
Breast 4 2 0 0 0 0 1 3 14 7
Others 10 0 0 0 5 0 6 1 33 0
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neutropenia by the total number of participants for each
docetaxel dose, were 70.1, 68.9, 50.0, and 75.3% for 60,
70, 75, and 100 mg/m2, respectively.
Logistic regression
The results from the univariate and multivariate logistic
regression analyses are shown in Table 2. From the univar-
iate analysis, studies conducted in Asia (p = 0.073), treat-
ment line (p = 0.057), and the percentage of females
(p = 0.082) were included in the subsequent multivariate
analysis. The dose of docetaxel (p = 0.266), the median age
of participants (p = 0.300), and the percentage of patients
whose performance status was[1 (p = 0.287) did not meet
the criteria, but were forcibly included in the subsequent
multivariate analysis. Trial phase (p = 0.276) was excluded.
Multivariate analysis identified studies conducted in Asia
[odds ratio (OR) 19.0; 95% confidence interval (95% CI)
3.64–99.0; p \ 0.001] and the dose of docetaxel (OR 1.08;
95% CI 1.03–1.13; p = 0.001) as independent variables for
the incidence of grade 3/4 neutropenia. The percentage of
patients whose performance status was[1 (OR 0.99; 95% CI
0.96–1.02; p = 0.444) and the median age of participants
(OR 1.02; 95% CI 0.94–1.10; p = 0.598) were not identified
as significant variables. The percentage of females and
treatment line were not included in the final model. The
Hosmer–Lemeshow goodness-of-fit test suggested a good
calibration (p = 0.492). The predictive accuracy of this
model was 76.6%.
Discussion
We confirmed that docetaxel had a higher toxicity in Asian
studies than in non-Asian studies. The studies performed in
Asia showed an almost 19 times higher risk for severe
neutropenia compared with the non-Asian studies.
Docetaxel has been one of the most important cytotoxic
drugs in the treatment of major tumors such as breast cancer,
non-small-cell lung cancer, and prostate cancer. This indi-
cates that docetaxel will be used as a reference regimen in
future clinical trials. However, the heterogeneity of doce-
taxel-induced toxicity profiles between Asian and non-Asian
countries is a major problem due to the resulting variations in
the recommended dose of docetaxel. This also represents a
serious concern in the clinical setting. Physicians and phar-
macists should consider ethnic diversity in docetaxel toxicity
when interpreting the results of clinical trials.
One of the possible mechanisms that influence the ethnic
diversity in docetaxel toxicity is pharmacogenomic differ-
ences in drug-metabolizing enzymes and/or drug transport-
ers. Recently, a US–Japan common-arm trial reported
diversity in the clinical outcomes, including survival and
neutropenia, between US and Japanese non-small-cell
Fig. 2 Incidence of severe neutropenia. The incidence of grade 3/4
neutropenia reported in each paper was plotted. Each symbol
represents a treatment arm that included a single-agent docetaxel
arm. The open circles represent studies conducted in non-Asian
countries. The asterisks represent studies conducted in Asian
countries. The horizontal bars represent the weighted means of the
reported incidence of grade 3/4 neutropenia for each docetaxel dose,
for which sample size was used as a weight
Table 2 Logistic regression analysis
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Studies conducted in Asia 2.20 0.93–5.22 0.073 19.0 3.64–99.0 \0.001
Docetaxel dose 1.01 0.99–1.03 0.266 1.08 1.03–1.13 0.001
PS [1 0.99 0.96–1.01 0.287 0.99 0.96–1.02 0.444
Median age 0.97 0.91–1.03 0.300 1.02 0.94–1.10 0.598
Percentage of female 1.01 1.00–1.02 0.082 Excluded
Treatment line (C2nd line) 0.50 0.24–1.02 0.057 Excluded
OR odds ratio, CI confidence interval, PS [1 percentage of the participants whose performance status was [1
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cancer patients who received the same cytotoxic chemo-
therapy regimen, paclitaxel plus carboplatin [128]. The
researchers discussed the possible causes of these differ-
ences and suggested that the allelic distribution of the genes
involved in paclitaxel disposition or DNA repair was a sig-
nificant factor. Such an approach may be very useful in
determining the mechanisms that cause ethnic differences in
drug effects and toxicity. Docetaxel pharmacokinetics is
dominated by the hepatic cytochrome P450 3A (CYP3A)
subfamily and P-glycoprotein, which are partly involved in
paclitaxel disposition [129]. These facts indicate that similar
pharmacogenomic differences might have some role in the
ethnic differences in docetaxel toxicity. Population phar-
macokinetic studies of docetaxel were performed in Western
countries and Japan to harmonize drug development in the
two regions. In these studies, researchers concluded that the
systemic clearance of docetaxel was almost similar between
Western and Japanese participants with the same variables,
including hepatic function, serum albumin level, serum a1-
acid glycoprotein (AAG) level, and age [130, 131].
Individualized dosing of docetaxel is one of the potential
solutions for pharmacoethnicity. On the other hand, there
are many barriers and unknown variables in achieving
satisfactory individualization. Yamamoto et al. [132]
reported that docetaxel dosing based on CYP3A function
using the hydration ratio of externally administered cortisol
as a probe improved pharmacokinetic variability, but not
pharmacodynamic variability. These results indicate a
possible divergence in systemic pharmacokinetics and
local exposure of the drug. Systemic exposure of cytotoxic
agents is not the only factor but is one of the major factors
that influence myelotoxicity, because drug transport into
hematopoietic progenitor cells may be a critical point in the
differential expression of toxicity [133, 134].
Our study has some limitations in terms of design. The
classification criterion used in our analysis might not
accurately reflect the ethnicity of the participants because
we classified studies by the region in which they were
mainly conducted, not by the race of the participants. We
decided to use this criterion because most of the published
studies did not report the demographic background of the
participants with respect to race. We believe that the results
of our study might reflect not only racial differences but
also other regional factors such as environment and social
divergence. This study was based on the published data,
which were aggregated as means or medians; however, this
approach loses considerable information about each par-
ticipant. For example, the effects of some variables
including the patients’ age and performance status, which
are known to be variables that affect chemotherapy-
induced neutropenia, were not significant in our study. In
addition, we could not obtain some variables for the
majority of the study subjects. For example, the interval of
complete blood count (CBC interval) monitoring affects
the incidence of severe neutropenia. Only 84 of the 128
arms (65%) contained information about the CBC interval.
In the sub-analysis using these 84 arms, the CBC interval
showed a significant negative relationship with outcome in
the univariate analysis. Bruno et al. [135] reported that the
AAG level, docetaxel clearance, baseline count of neutro-
phils, and number of previous regimens were significant
predictors of grade 4 neutropenia. In our analysis, we could
not obtain data on the AAG level from each paper because
it was not routinely measured in the clinical setting or
clinical trials. The baseline neutrophil count and hepatic
enzyme level were not taken into consideration in our
analysis because most of the studies have eligibility criteria
according to blood cell counts and blood chemicals.
In conclusion, there is a significant difference in the
incidence of docetaxel-induced severe neutropenia
between Asian and non-Asian studies. Physicians and
pharmacists should therefore consider ethnic diversity in
docetaxel toxicity when interpreting the results of clinical
trials.
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